United States: Reverse Payments, Actavis, and the Lower Courts at Sea, Part 2: The Brewing Conflict Over Non-Cash Settlements

Our first post in this series was titled "What Is a Reverse Payment?" As the recent cases discussed in today's post show, the courts are struggling with a fundamental component of that question: What, for that matter, is a payment?

Among the issues left unresolved by the Supreme Court's Actavis opinion is the question of whether a reverse payment settlement can run afoul of antitrust laws when no actual cash changes hands. Instead, these arrangements might include a promise by the brand name manufacturer to delay the introduction of an authorized generic, a settlement of unrelated litigation on terms beneficial to the generic manufacturer, or a licensing agreement whereby the generic manufacturer gains rights to market the brand name product overseas. These can be of tremendous value to the generic manufacturer, but they are different from the "pay[ment of] many millions of dollars" that was the focus of Justice Breyer's opinion for the Actavis majority.

According to the FTC, the potentially anticompetitive effect of these settlements is no different: in return for some form of consideration, the generic manufacturer agrees to delay its entry of a product that would drive down prices paid by consumers. But the Actavis Court did not state explicitly whether non-cash settlements are included in its holding, and the district courts that have struggled with the question—including three in the past month alone—have reached inconsistent results.

The "'Payment' Means Cash" Opinions

On one side are the judges who note that both the majority and the dissenting opinions in Actavis "reek with discussion of payment of money." The first of these, Judge Walls of the District of New Jersey, acknowledged this past January in the Lamictal[1] litigation that a non-monetary settlement is at least "within the gestalt of Actavis." However, because both the facts in Actavis and the words in its opinions revolved around cash payments, he concluded that "good jurisprudence" counseled him not to "extend the holding of Actavis to . . . non-monetary facts."

The FTC, a strident opponent of reverse payment settlements, filed an amicus brief with the Third Circuit urging reversal of the Lamictal decision. Oral argument on the appeal will likely take place in late 2014 or early 2015.

The District of Rhode Island recently followed Judge Walls' lead in the Loestrin 24[2] case, characterizing the Supreme Court's focus on cash payments as a "fixation." It also noted that the factors the Actavis Court instructed lower courts to use in evaluating reverse payment settlements all require an assessment of the value of the consideration in the context of the facts of the settlement. A non-cash settlement "is almost impossible to measure" against those factors. The court went on to say that it was loath to extend Actavis beyond its facts and language, since that case already represents such a "significant change in direction."

The Rhode Island court explained that it was not without "reservations" about the holding and that its decision was a "close call." Echoing Chief Justice Roberts' dissenting opinion, the court bemoaned the difficulty created for lower courts by the Actavis decision.

The "Non-Monetary Payments are Payments Too" Opinions

By sheer numbers, the "payment means cash" opinions are in the slight minority at this early stage. Courts for the District of Massachusetts and the Eastern District of Pennsylvania, along with Judge Walls' colleague, Judge Sheridan of the District of New Jersey, have issued opinions stating that Actavis is not limited to cases involving monetary payments. Two of those decisions, in the Niaspan[3] and Lipitor[4] cases, relied on the broad gloss given to the word "payment" by Black's Law Dictionary and court opinions from other contexts.

Meanwhile, these courts point out that nowhere in the Actavis decision did the Court exclude non-monetary settlements from its reach; indeed, the Lipitor court noted, "it is clear that the Supreme Court focuses on the antitrust intent of the settling parties rather than the manner of payment." Furthermore, in litigation relating to the acid reflux drug Nexium[5] the District of Massachusetts suggested that to restrict the Actavis holding to monetary payments would fail to align the law with "modern-day realities," citing the FTC's statements that non-monetary settlements are just as much a part of the perceived "pay-for-delay" scourge as cash payments.

A Heavy Burden

Still, the plaintiff's road in a case involving non-monetary settlements will not be an easy one, even in a district where such settlements are recognized as falling under Actavis. The Lipitor court, despite finding that non-cash settlements can trigger antitrust liability, dismissed the complaint with prejudice. It found that the plaintiffs had failed to satisfy the "plausibility" pleading requirement imposed by Iqbal and Twombly, as overlain on the new Actavis regime. The court reasoned that a complaint must provide a reliable estimate of the monetary value of the non-monetary settlement in order to engage in the proportionality analysis—i.e. the question of whether the settlement amount is too "large"—required by Actavis. Since plaintiffs had not attempted to provide such an estimate, the complaint had to be dismissed.

Diligent plaintiffs will have to include in their pleadings some reasonably compelling methodology by which to value non-monetary reverse payment settlements. That is, assuming such settlements are found by the appellate courts to fall under Actavis at all. Stay tuned.


>

[1] In re Lamictal Direct Purchaser Antitrust Litig., No. 12-cv-995, 2014 U.S. Dist. LEXIS 9257 (D.N.J. Jan. 24, 2014). The settlement at issue in the Lamictal litigation provided the generic manufacturer with the assurance, essentially, that when its products came to market they would not face competition from the brand manufacturer's authorized generic for a certain period of time.

[2] In re Loestrin 24 FE Antitrust Litig., No. 13-md-2472, 2014 U.S. Dist. LEXIS 123322 (D.R.I. Sept. 4, 2014). The settlements at issue in Loestrin 24 included promises by the brand manufacturer to delay launch of an authorized generic and not to license other generics for a certain period; a grant of licensing rights for branded products to the generic manufacturer; and licenses and co-promotion agreements with respect to branded drugs that were unrelated to the underlying patent litigation.

[3] In re Niaspan Antitrust Litig., No. 13-md-2460, 2014 U.S. Dist. LEXIS 124818 (E.D. Pa. Sept. 5, 2014). In Niaspan, the disputed settlement included a delay of authorized generics; a royalty payment to the generic manufacturer for sales of Niaspan and a separate drug; a co-promotion agreement; and a cash payment that was ostensibly made in exchange for the generic manufacturer's agreement to develop manufacturing processes for Niaspan and another drug, and to act as a back-up supplier for those products.

[4] In re Lipitor Antitrust Litig., No. 12-cv-02389, 2014 U.S. Dist. LEXIS 127877 (D.N.J. Sept. 12, 2014). The settlement agreement at issue in the Lipitor case included the settlement of overseas litigation and litigation concerning a separate product on terms that the antitrust plaintiffs claimed were so forgiving to the generic manufacturer as to constitute a "sweetheart" deal. The generic manufacturer was also awarded overseas licensing rights to the disputed product.

[5] In re Nexium (Esomeprazole) Antitrust Litig., 968 F. Supp. 2d 367 (D. Mass. 2013). In relevant part, the settlement at issue in the Nexium case involved a "no authorized generic" promise by the brand name manufacturer.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions